rescribing Information of fulvestrant for infertility information.
Drug Interactions
Advise patients to avoid the use of strong CYP3A4 inducers in patients treated with PIQRAY. Advise patientsto avoid the use of BCRP inhibitors in patients treated with PIQRAY. If unable to use alternative drugs, closelymonitor for increased adverse reactions. Advise patients that close monitoring may be required when PIQRAY is coadministered with CYP2C9 substrates where decreases in the plasma concentration of CYP2C9 substratesmay reduce activity of these drugs [see Drug Interactions (7.1, 7.2)].
Dosing
Instruct patients to take PIQRAY at approximately the same time each day and to swallow the tablet(s)whole (tablets should not be chewed, crushed, or split prior to swallowing) [see Dosage andAdministration (2.2)].
Advise patients to take PIQRAY with food [see Drug Interactions (7.4)].
Instruct patients that if a dose of PIQRAY is missed, it can be taken with food within 9 hours after thetime it is usually taken. After more than 9 hours, skip the dose for that day. The next day, take PIQRAYat the usual time. Instruct patients not to take 2 doses to make up for a missed dose.
Instruct patients that if they vomit after taking the dose of PIQRAY, they should not take an additionaldose on that day, and to resume the usual dosing schedule the next day at the usual time [see Dosageand Administration (2.2)].
Distributed by:
Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936
© Novartis
T2019-57
https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/piqray.pdf
|
